Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Pirtobrutinib by Eli Lilly and Co for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Pirtobrutinib is under clinical development by Eli Lilly and Co and currently in Phase III for Refractory Chronic Lymphocytic Leukemia...
Data Insights
Pirtobrutinib by Eli Lilly and Co for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Pirtobrutinib is under clinical development by Eli Lilly and Co and currently in Phase III for Relapsed Chronic Lymphocytic Leukemia...